Ark Biosciences, a Shanghai biotech developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, successfully completed a phase I clinical trial of its anti-respiratory syncytial virus (RSV) drug AK0529. The trial is a randomized, double-blind, placebo-controlled study of orally administered AK0529 that evaluates safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses. Ark had completed a Series A round led by Qiming and Morningside in April 2015 to help fund the advancement of AK0529.
